AR-623 (LIPOSOMAL-TRETINOIN) IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA

AR-623（脂质体维A酸）治疗急性早幼粒细胞白血病患者

• 批准号: 6113622
• 负责人: DAN DOUER
• 金额: $ 3.56万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6113622
• 关键词: acute myelogenous leukemia; antineoplastics; clinical research; drug screening /evaluation; human subject; liposomes; neoplasm /cancer chemotherapy; neoplasm /cancer nutrition therapy; neoplasm /cancer relapse /recurrence; nutrition related tag; retinoate

The purpose of this study is to estimate the effectiveness of AR-623 inducing a complete remission in first relapse acute promyocytic leukemia (APL) patients who have not received oral all-trans-retinoic acid (ATRA) within one year.

本研究的目的是评估 AR-623 在一年内未接受口服全反式维甲酸 (ATRA) 的首次复发急性早幼细胞白血病 (APL) 患者中诱导完全缓解的有效性。